Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl3 nigrostriatal lesions

Movement Disorders

Volumn 16, Issue 3, 2001, Pages 424-434

  Datla, Krishna P ^a   Blunt, Stavia B ^a   Dexter, David T ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

L DOPA; Neurodegenerative; Neuroprotection; Oxidative stress; Parkinson's disease

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID ISOPROPYL ESTER; ASCORBIC ACID; BENSERAZIDE; DRINKING WATER; FERRIC CHLORIDE; LEVODOPA; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN INJURY; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; CYTOTOXICITY; DOPAMINE METABOLISM; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; IMMUNOCYTOCHEMISTRY; LONG TERM CARE; MALE; NERVE ENDING; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; RAT;

ADRENERGIC AGENTS; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; BENSERAZIDE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FERRIC COMPOUNDS; IMMUNOENZYME TECHNIQUES; LEVODOPA; MALE; NEOSTRIATUM; NERVE NET; NEURONS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 0035353737     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1091     Document Type: Article

References (33)

1. DeJong GJ, Meervaldt JD, Schmitz PIM. Factors that influence the occurrence of response variations in Parkinson's disease. Ann Neurol 1987;22:4-7.
2. Lesser RP, Fahn S, Snider SR, et al. Analysis of the clinical problems in Parkinsonism and the complications of long-term levodopa therapy. Neurology 1979;29:1253-1260.
3. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978;14: 633-643.
4. Spencer JPE, Jenner A, Butler J, et al. Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. Free Rad Res 1996;24:95-105.
5. Mena MA, Pardo B, Casarejos MJ, et al. Neurotoxicity of levodopa on catecholamine rich neurones. Mov Disord 1992;7:23-31.
6. Mena MA, Pardo B, Paino CL, de Yebenes JG. Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid. Neuroreport 1993;4:438-440.
7. Spencer JPE, Jenner A, Aruoma OI, et al. Intense oxidative DNA damage promoted by L-DOPA and its metabolites: implications for neurodegenerative disease. FEBS Lett 1994;353:246-250.
8. Mena MA, Casarejos MJ, Carazo A, et al. Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicity. Neuroreport 1996;7:441-445.
9. Spencer-Smith T, Parker WD, Jr, Bennett JP, Jr. L-DOPA increases nigral production of hydroxyl radicals in vivo: potential I-DOPA toxicity? Neurosci Lett 1994;5:1009-1011.
10. Obata T, Yamanaka Y. Protective effect of carbidopa on hydroxyl radical generation in the rat striatum by dopamine. Neurosci Lett 1996;221:13-16.
11. Camp DM, Loeffler DA and LeWitt PA. L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion. J Neurochem 2000;74:1229-1240.
12. Ogawa N, Asanuma M, Kondo Y, et al. Differential effects of chronic L-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-OHDA. Neurosci Lett 1994;171:55-58.
13. Hefti F, Melamed E, Bhawan J, Wurtman RL. Long-term administration of L-DOPA does not damage dopaminergic neurone in the mouse. Neurology 1981;31:1194-1195.
14. Perry TL, Yong VW, Foulks JG, et al. Nigrostriatl dopaminergic neurones remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem 1984;43:990-993.
15. Quinn NP, Parkes D, Janota I, Marsden CD. Case report: preservation of the substantia nigra and the locus coeruleus in a patient receiving levodopa plus decarboxylase inhibitor over a four year period. Mov Disord 1986;1:65-68.
16. Dexter DT, Wells FR, Agid F, Agid Y, et al. Increased nigral iron content in post-mortem parkinsonian brain. Lancet 1987;ii:1219-1220.
17. Sengstock GJ, Olanow CW, Dunn AJ, Arendash GW. Iron induces degeneration of nigrostriatal neurons. Brain Res Bull 1992;28: 645-649.
18. 3H] Mazindol autoradiography. Neuroscience 1991;43:95-110.
19. Dexter DT, Nanayakkara I, Goss-Sampson MA, et al. Nigral dopaminergic cell loss in vitamin E deficient rats. NeuroReport 1994; 5:1773-1776.
20. Carman LS, Gage FH and Shults CW. Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. Brain Res 1991;553:275-283.
21. Hirata H, Ladenheim B, Carlson E, et al. Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice. Brain Res 1996;714:95-103.
22. Paxinos G, Watson C. The rat brain in stereotaxic co-ordinates. ed 2. London, U.K.: Academic Press Ltd. 1986.
23. Sullivan AM, Opacka-Juffry J, Blunt SB. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotropic factor against 6-hydroxydopamine in vivo. Eur J Neurosci 1998;10:57-63.
24. Datla KP, Curzon G. Effect of p-chlorophenylalanine at moderate dosage on 5-HT and 5-HIAA concentrations in brain regions of control and p-chloroamphetamine treated rats. Neuropharmacology 1996;35:315-320.
25. Murer G, Dziewczapilski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998;43:561-575.
26. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res 1997;767:340-344.
27. Bowenkamp KE, David D, Lapchak PL, Henry MA, Granholm AC, Hoffer BJ, Mahalik TJ. 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra. Exp Brain Res 1996;111:1-7.
28. Hirsch E, Graybiel AM, Agid Y. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345-348.
29. Jeon BS, Jackson-Lewis V, Burke RE. 6-Hydroxtdopamine lesion of the rat substantia nigra;time course and morphology of cell death. Neurodegeneration 1995;4:131-137.
30. Hastings TG, Lewis DA, Zigmond MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injection. Proc Natl Acad Sci USA 1996;93:1956-1961.
31. Okazawa H, Murata M, Watanabe M, Kamei M, Kanazawa I. Dopaminergic stimulation up-regulates in vivo expression of brain-derived neurotrophic factor (BDNF) in the striatum. FEBS Lett 1992;313:138-142.
32. Carvey PM, Ptak LR, Nath ST. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures. Exp Neurol 1993;120:149-152.
33. Han SK, Mytilineou C, Cohen G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996;66:501-510.